5 Results

People

  1. Drilon
    Drilon
  2. Ladanyi
    Ladanyi
  3. Odintsov
    Odintsov
  4. Schram
    Schram
  5. Somwar
    Somwar
  6. Asher
    Asher
  7. Daly
    Daly
  8. De Stanchina
    De Stanchina
  9. Delasos
    Delasos
  10. Khodos
    Khodos

Groups

  1. Department of Medicine (4)
  2. Solid Tumor Oncology Division (4)
  3. Thoracic Oncology (3)
  4. Department of Pathology and Laboratory Medicine (2)
  5. Early Drug Development Service (2)
  6. GSK Faculty (2)
  7. Gynecologic Medicine Service (2)
  8. Human Oncology and Pathogenesis Program (2)
  9. Sloan Kettering Institute Postdocs (2)
  10. Tow Center for Developmental Oncology (TCDO) (2)
  1. "nrg1 fusion"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (1)
Groups
  1. Department of Medicine (4)
  2. Solid Tumor Oncology Division (4)
  3. Thoracic Oncology (3)
  4. Department of Pathology and Laboratory Medicine (2)
  5. Early Drug Development Service (2)
  6. GSK Faculty (2)

More Groups

People
  1. Alexander Drilon (2)
  2. Alison Schram (2)
  3. Igor Odintsov (2)
  4. Marc Ladanyi (2)
  5. Romel Somwar (2)
  6. Christopher Kurzatkowski (1)

More People

Years
  1. 2024 (2)
  2. 2021 (3)
Publications
  1. Journal of Thoracic Oncology (3)
  2. Future Oncology (1)
  3. The Oncologist (1)
Publishers
  1. Elsevier Inc. (3)
  2. Future Medicine (1)
  3. Oxford University Press (1)

Results (5)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions
    Journal Article

    Kim, D. W.; Schram, A. M.; Hollebecque, A.; Nishino, K.; Macarulla, T.; Rha, S. Y.; Duruisseaux, M.; Liu, S. V.; Al Hallak, M. N.; Umemoto, K.; more...
    Future Oncology (2024)

    Fulltext@MSK | Save
  • HER4 and EGFR activate cell signaling in NRG1 fusion-driven cancers: Implications for HER2-HER3-specific versus pan-HER targeting strategies
    Journal Article

    Udagawa, H.; Nilsson, M. B.; Robichaux, J. P.; He, J.; Poteete, A.; Jiang, H.; Heeke, S.; Elamin, Y. Y.; Shibata, Y.; Matsumoto, S.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • A phase I, first-in-human study of GSK2849330, an anti-HER3 monoclonal antibody, in HER3-expressing solid tumors
    Journal Article

    Gan, H. K.; Millward, M.; Jalving, M.; Garrido-Laguna, I.; Lickliter, J. D.; Schellens, J. H. M.; Lolkema, M. P.; Van Herpen, C. L. M.; Hug, B.; Tang, L.; more...
    The Oncologist (2021)

    Fulltext@MSK | Save
  • Novel preclinical patient-derived lung cancer models reveal inhibition of HER3 and MTOR signaling as therapeutic strategies for NRG1 fusion-positive cancers
    Journal Article

    Odintsov, I.; Mattar, M. S.; Lui, A. J. W.; Offin, M.; Kurzatkowski, C.; Delasos, L.; Khodos, I.; Asher, M.; Daly, R. M.; Rekhtman, N.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Phase 2 study of zenocutuzumab (MCLA-128), a bispecific HER2/HER3 antibody in NRG1 fusion-positive advanced solid tumors
    Meeting Abstract

    Schram, A.; Macarulla, T.; O'Reilly, E.; Rodon, J.; Wolpin, B.; Ou, S.; Kim, D.; Yang, J. C.; Lam, J.; De Langen, A.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save